ライフサイエンスコーパス: type O

1 splants on average, more if the NDD is blood type O.

2 2.03-3.54) compared with nonsmokers of blood type O.

3 lowing exposure to either Abca4(-/-) or wild-type OS.

4 owed by a temperature shift to 37 degrees C, type O(1)C3056R-KGE colocalized with caveolin-1, while O

5 Using a genetically engineered variant of type O(1)Campos (O(1)C3056R) which can utilize both inte

6 The rNV VLPs hemagglutinated all human type O (11 of 11), A (9 of 9), and AB (4 of 4) RBCs; how

7 s results in GBS, and 1 of 158 Campylobacter type O:19 infections results in GBS.

8 of new multielectron catalysts for oxygenase-type O(2) activation, as well as the microscopic reverse

9 r (N-acetylglucosamine or GlcNAc), show wild-type O(2) dependence of culmination, cells lacking AgtA,

10 icipants by genotype-derived serologic blood type (O, A, AB, and B).

11 ation assays; GST-VP8* P[11] hemagglutinates type O, A, and B red blood cells as well as pooled umbil

12 The incidence rates for blood types O, A, AB, and B were 28.9, 39.9, 41.8, and 44.5 ca

13 nal antibody was shown to recognize the wild-type O-acetylated CPS, but not the CPS of the mynC mutan

14 In a given cell type, O-acetylation can also be specific to a particular

15 n an acquired ability to infect CHO cells by type O and Asia-1 FMDV.

16 Patients with ABO blood type O and B have smaller chances.

17 n pathway and can produce well defined human-type O- and N-linked glycans on recombinant therapeutics

18 hat it lacked the terminal sugar of the wild-type O antigen, 2,3,4-tri-O-methylfucose.

19 omotrimeric tailspike that cleaves the O18A1 type O antigen.

20 ype (4.9% stillbirths, 3.0% live births) (vs type O; AOR, 1.96 [95% CI, 1.16-3.30]); history of drug

21 lation followed by an intramolecular Ullmann-type O-arylation.

22 -list mortality; however, infants with blood type O assigned an ABO-I listing strategy were more like

23 <0.003), UNOS status I and II (P<0.007), ABO type O, B, and AB (P<0.03), and reduced-size/split liver

24 bAC) 103 (7%), alpha thalassaemia 438 (28%), type O blood group 621 (40%), and G6PD deficiency 72 (9%

25 Candidates listed for LTx with type O blood had better clinical status at evaluation, b

26 The 308 candidates with type O blood waited longer for LTx (median 109 days) tha

27 accomplishes the conversion of regular human type-O blood into a potential blood substitute for the r

28 LTx candidates with other blood types, blood type O candidates have longer waiting times and higher p

29 2 and protein tyrosine phosphatase, receptor type, O cooperated with the v-raf murine sarcoma viral o

30 the H-antigen trisaccharide from human blood type O erythrocytes, at 1.67 angstrom resolution.

31 orm of protein tyrosine phosphatase receptor type O expressed predominantly in hematopoietic cells, i

32 Here, we produced mucin-type O-GalNAc and core 1 O-linked glycan structures on r

33 n, the protein-tyrosine phosphatase receptor type O gene, PTPRO, was frequently methylated in right-s

34 Mucin-type O-gly co sy la tion is initiated by a large family

35 l transferases (ppGalNAc Ts) initiates mucin-type O-glycan biosynthesis at serine and threonine.

36 Mucin-type O-glycan biosynthesis is regulated by the family of

37 alNAcalpha1-Ser/Thr (T antigen) during mucin type O-glycan biosynthesis.

38 TCR avidities, perforin levels, and surface type O-glycan levels indicative of mature CD8(+) T cell

39 e2 O-glycan is presumably an essential mucin-type O-glycan structure found in both molecules in vivo.

40 hether such differential expression of mucin-type O-glycan structures has physiological significance

41 c-R is the precursor for many extended mucin-type O-glycan structures in animal cell surface and secr

42 e first to clearly identify functional mucin-type O-glycan structures modulating cell surface express

43 Mucin-type O-glycan structures were analyzed at both stages by

44 Here, we compared expression of mucin-type O-glycan synthases from proliferating and different

45 now identify a sulfated extended core1 mucin-type O-glycan, Gal beta 1-->4(sulfo-->6)GlcNAc beta 1-->

46 Mucin-type O-glycans (O-glycans) are highly expressed in vascu

47 muscle-specific domain (MSD) to which mucin type O-glycans are attached.

48 Mucin-type O-glycans are classified according to their core st

49 rate ligands that reveal how host cell mucin-type O-glycans are recognized and allow a structure-guid

50 talytic preference for core 2-branched mucin-type O-glycans as found in natural L-selectin counterrec

51 Poly-N-acetyllactosamines in mucin-type O-glycans can be formed in core 2 branched oligosac

52 Mucin-type O-glycans could be imaged as early as 7 hours postf

53 Mucin-type O-glycans form one of the most abundant and complex

54 gen), the precursor structure for most mucin-type O-glycans in a wide variety of glycoproteins.

55 This study identified the most common mucin-type O-glycans in human tears and their expected biosynt

56 one Cosmc regulate the biosynthesis of mucin type O-glycans on glycoproteins, and evidence suggests t

57 ults indicate that polysialic acid and mucin type O-glycans on NCAM differentially regulate myoblast

58 ive method used to amplify and profile mucin-type O-glycans synthesized by living cells.

59 tructural evidence for a novel type of mucin-type O-glycans that is strictly specific for LacdiNAc te

60 a pivotal role in the biosynthesis of mucin-type O-glycans that serve as ligands in cell adhesion.

61 cular surface epithelium to synthesize mucin-type O-glycans to maintain a wet-surface phenotype.

62 Mucin type O-glycans with core 2 branches are distinct from no

63 se (C1GALT1) controls the formation of mucin-type O-glycans, far overlooked and underestimated in can

64 gates (O-fucose, O-mannose, N-glycans, mucin-type O-glycans, proteoglycans, glycosphingolipids), focu

65 lactosamine moieties for inhibition of mucin-type O-glycans.

66 predicted to act in the synthesis of core-1 type O-glycans.

67 -Ser/Thr) is an important precursor of mucin-type O-glycans.

68 Mucin-type O-glycoproteins are present abundantly in bone, whe

69 amine residues, which are present in a mucin-type O-glycosidic linkage.

70 mary, this study demonstrates that mammalian type O-glycosylation can be established in plants and th

71 understanding of the diverse roles of mucin-type O-glycosylation during eukaryotic development.

72 Here we show that the N-acetylgalactosamine-type O-glycosylation enzyme GALNT11 is crucial to such d

73 reviously unrecognized requirement for mucin-type O-glycosylation in epithelial tube integrity and ha

74 have demonstrated essential roles for mucin-type O-glycosylation in protein secretion, stability, pr

75 Mucin type O-glycosylation is a highly conserved form of post-

76 Mucin-type O-glycosylation is an evolutionarily conserved prot

77 Mucin-type O-glycosylation is an important post-translational

78 The initiation of mucin-type O-glycosylation is catalyzed by a family of UDP-Gal

79 Mucin-type O-glycosylation is initiated by a family of UDP-Gal

80 Mammalian mucin-type O-glycosylation is initiated by a large family of a

81 Mucin type O-glycosylation is initiated by a large family of p

82 Mucin-type O-glycosylation is initiated by a large family of U

83 Mucin-type O-glycosylation represents a major form of post-tra

84 ific inhibitors, and the prediction of mucin-type O-glycosylation sites.

85 Since in mucin type O-glycosylation sugars are added individually and s

86 In summary, stably engineered mammalian type O-glycosylation was established in transgenic plant

87 Abnormal N- and mucin type O-glycosylation was found on serum proteins, and re

88 Abnormal N- and/or mucin type O-glycosylation was observed in all patients tested

89 ted individuals showed abnormal N- and mucin-type O-glycosylation, and mass spectrometry indicated re

90 l-D-galactosamine (GalNAc) (core-1) in mucin type O-glycosylation, and thus terminates chain extensio

91 (EC 2.4.1.41) of enzymes that initiate mucin-type O-glycosylation, are structurally composed of a cat

92 ransferases (GalNAc-Ts), that initiate mucin-type O-glycosylation, consist of a catalytic and a lecti

93 Long term inhibition of mucin-type O-glycosylation, sialylation, or sulfation altered

94 Because plants are devoid of GalNAc-type O-glycosylation, we have assessed requirements for

95 oat, can now be ascribed to defects in mucin-type O-glycosylation.

96 of up to 20 transferases that initiate mucin-type O-glycosylation.

97 ate the involvement of GalNAc-type (or mucin-type) O-glycosylation in EMT process, induced with trans

98 Mucin-type (N-acetylgalactosamine [GalNAc]-type) O-glycosylation is found in eumetazoan cells but a

99 (302) or Q(375) in VA387 affected binding to type O HBGA only, while switch mutants with three amino

100 m MOH to VA387 resulted in a weak binding to type O HBGAs.

101 bling species Paramecium septaurelia, mating type O is determined by coding-sequence deletions in a d

102 e transmembrane protein mtA, and the default type O is determined during development by scnRNA-depend

103 The pig type O isolate was not closely related to that recovered

104 Mucin-type O-linked glycoproteins are involved in a variety of

105 y numerous cell types and installed on mucin-type O-linked glycoproteins by the ppGalNAcTs.

106 n addition, GalNAz efficiently labeled mucin-type O-linked glycoproteins expressed at endogenous leve

107 erein we present a method for labeling mucin-type O-linked glycoproteins with a unique chemical tag,

108 The ability to label mucin-type O-linked glycoproteins with chemical tags should fa

109 the ppGalNAcTs makes the prediction of mucin-type O-linked glycosylation difficult based on primary s

110 Changes in mucin-type O-linked glycosylation in breast cancer can result

111 aNTases) is responsible for initiating mucin-type O-linked glycosylation in higher eukaryotes.

112 ere, we provide the first example that mucin-type O-linked glycosylation is involved in a development

113 Our studies suggest that mucin-type O-linked glycosylation may be required for normal d

114 ium, but not Plasmodium, possesses an animal-type O-linked glycosylation pathway, along with >30 pred

115 In mucin-type O-linked glycosylation these changes can result in

116 hanistically similar to that of animal mucin type O-linked glycosylation, except that it occurs in th

117 Mucin-type O-linked oligosaccharides (O-glycans) are primary c

118 Mucin-type O-linked oligosaccharides were directly released by

119 ows the structural characterization of mucin-type O-linked oligosaccharides.

120 tion of the GALNT enzyme in initiating mucin type O-linked protein glycosylation.

121 (ppGaNTases) initiate the formation of mucin-type, O-linked glycans by catalyzing the transfer of alp

122 Among different types, O-linked or mucin-type oligosaccharides are intim

123 were more blood type O recipients than blood type O NDDs participating.

124 The 40 blood type O NDDs triggered a mean chain length of 6.0 (median

125 n = 90) was greater than the number of blood type O-non-directed donors (n = 32) initiating chains.

126 d with the MBL genotype (A/A indicating wild type, O/O indicating homozygous for MBL structural-gene

127 Especially highly sensitized and blood type O patients benefit.

128 The number of blood type O-patients receiving a transplant (n = 90) was grea

129 Further analyses identified a class II-type O-phosphoseryl-tRNA synthetase (SepRS) and Sep-tRNA

130 he rat protein tyrosine phosphatase receptor type O (PTPRO) and one amplified gene as rat C-MYC.

131 ne for protein tyrosine phosphatase receptor-type O (PTPRO) in primary and established rat hepatomas.

132 elated)] and the type III RPTP, PTP receptor type O (PTPRO), have been implicated in the regulation o

133 Protein tyrosine phosphatase receptor type O (PTPRO), which is required for Eph receptor-depen

134 orm of protein-tyrosine phosphatase receptor-type O (PTPROt) is specifically expressed in hematopoiet

135 ype 2 antibody inhibited rNV VLP HA of human type O RBCs.

136 unctions as the rNV VLP HA receptor on human type O RBCs.

137 antigens also inhibited rNV VLP HA of human type O RBCs.

138 There were more blood type O recipients than blood type O NDDs participating.

139 One hundred thirty-three blood type O recipients were transplanted.

140 RBCs from healthy universal donors (type O, Rh negative) were incubated with SLE or control

141 Incubation of RBC from universal donors (type O, Rh negative) with trauma sera (n = 10) promoted

142 s indicate that in vitro cultivation of FMDV type O selects viruses that bind to heparin and that vir

143 Compared with blood type O, the ORs for pancreatic cancer in subjects with t

144 developmentally regulated PTP, PTP receptor-type O truncated (PTPROt).

145 In contrast, both type O viruses utilized alpha(V)beta(6) and alpha(V)beta

146 exchanges to ensure that the standard blood type O wait-list candidates are made better off.

147 problematic because it harms standard blood type O wait-list candidates who already have the longest

148 Transplantation of bone marrow from wild-type o XBP1ecko mice could also slightly improve the foo